This company listing is no longer active
InterCure 과거 수익 실적
과거 기준 확인 4/6
InterCure has been growing earnings at an average annual rate of 32.3%, while the Pharmaceuticals industry saw earnings growing at 26.5% annually. Revenues have been growing at an average rate of 72% per year. InterCure's return on equity is 5.6%, and it has net margins of 7.8%.
주요 정보
32.3%
수익 성장률
25.1%
EPS 성장률
| Pharmaceuticals 산업 성장 | 23.1% |
| 매출 성장률 | 72.0% |
| 자기자본 수익률 | 5.6% |
| 순이익 | 7.8% |
| 최근 수익 업데이트 | 31 Mar 2023 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
InterCure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 31 Mar 23 | 408 | 32 | 109 | 1 |
| 31 Dec 22 | 389 | 45 | 102 | 1 |
| 30 Sep 22 | 363 | 33 | 96 | 1 |
| 30 Jun 22 | 324 | 24 | 80 | 1 |
| 31 Mar 22 | 274 | 15 | 67 | 1 |
| 31 Dec 21 | 220 | 5 | 57 | 1 |
| 30 Sep 21 | 167 | 17 | 43 | 1 |
| 30 Jun 21 | 128 | 20 | 35 | 2 |
| 31 Mar 21 | 94 | 13 | 30 | 2 |
| 31 Dec 20 | 65 | -37 | 27 | 2 |
| 30 Sep 20 | 40 | -63 | 26 | 2 |
| 30 Jun 20 | 20 | -80 | 32 | 2 |
| 31 Mar 20 | 11 | -91 | 41 | 2 |
| 31 Dec 19 | 9 | -6 | 83 | 2 |
| 30 Sep 19 | 7 | 7 | 81 | 1 |
| 30 Jun 19 | 5 | 18 | 72 | 0 |
| 31 Mar 19 | 2 | 27 | 58 | 0 |
| 31 Dec 18 | 0 | -13 | 10 | 0 |
| 30 Sep 18 | 0 | -10 | 5 | 0 |
| 30 Jun 18 | 0 | -8 | 1 | 0 |
| 31 Mar 18 | 0 | -7 | 1 | 0 |
| 31 Dec 17 | 0 | -6 | 1 | 0 |
| 30 Sep 17 | 0 | -4 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | 0 | 1 | 0 |
| 30 Sep 16 | 0 | 0 | 2 | 0 |
| 30 Jun 16 | 0 | -1 | 2 | 0 |
| 31 Mar 16 | 1 | 0 | 2 | 0 |
| 31 Dec 15 | 1 | -2 | 2 | 0 |
| 30 Sep 15 | 2 | -1 | 3 | 0 |
| 30 Jun 15 | 3 | -2 | 3 | 0 |
| 31 Mar 15 | 4 | -4 | 4 | 0 |
| 31 Dec 14 | 6 | -4 | 6 | 0 |
| 30 Sep 14 | 7 | -5 | 6 | 0 |
| 30 Jun 14 | 7 | -5 | 6 | 0 |
| 31 Mar 14 | 8 | -6 | 7 | 0 |
| 31 Dec 13 | 8 | -7 | 8 | 0 |
| 30 Sep 13 | 8 | -6 | 10 | 0 |
| 30 Jun 13 | 8 | 43 | 10 | 0 |
| 31 Mar 13 | 8 | 44 | 9 | 0 |
| 31 Dec 12 | 8 | 43 | 8 | 0 |
| 30 Sep 12 | 9 | 47 | 7 | 1 |
양질의 수익: INCR.U has a large one-off gain of ₪9.8M impacting its last 12 months of financial results to March 31 2023.
이익 마진 증가: INCR.U's current net profit margins (7.8%) are higher than last year (5.4%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: INCR.U has become profitable over the past 5 years, growing earnings by 32.3% per year.
성장 가속화: INCR.U's earnings growth over the past year (113.2%) exceeds its 5-year average (32.3% per year).
수익 대 산업: INCR.U earnings growth over the past year (113.2%) exceeded the Pharmaceuticals industry 77.9%.
자기자본 수익률
높은 ROE: INCR.U's Return on Equity (5.6%) is considered low.